PCV2 Genotype 2b ORF2 Vaccine Cross-Protection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current vaccines for porcine circovirus type 2 (PCV2) face challenges in providing effective cross-protection against emerging genotypes, particularly PCV2d, as they often require high doses of ORF2 protein from the PCV2a genotype, which may not be sufficient for heterologous challenges and can interfere with other antigens in combination vaccines.
Innovation Solution
A vaccine using less than 20 µg of ORF2 encoded protein from PCV2 genotype 2b provides improved cross-protection against PCV2d, allowing for reduced antigen amounts while maintaining immunity, and can be administered in a single dose, even in the presence of maternal antibodies or at young ages.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If high doses of ORF2 protein from PCV2a genotype are used in vaccines, then immune response is enhanced, but antigen interference and vaccine volume increase
Solution Approach 1:
The patent changes the genotype parameter of the ORF2 protein from PCV2a to PCV2b, which fundamentally alters the antigenic properties and immune recognition characteristics. This parameter change enables effective cross-protection against PCV2d at lower doses, resolving the contradiction between immune response reliability and antigen quantity required
Solution Approach 2:
The patent uses PCV2b ORF2 protein as a surrogate antigen that copies the essential immunogenic features needed for cross-protection against PCV2d, without requiring the full dose of PCV2a protein. This copying approach maintains protective immunity while reducing antigen volume and interference
2Reliability
If high doses of ORF2 protein are administered, then cross-protection is achieved, but interference with other antigens in combination vaccines increases
Solution Approach 1:
By changing the genotype parameter to PCV2b, the patent modifies the antigenic profile to achieve cross-protection with reduced antigen dose, thereby minimizing interference effects on other vaccine antigens
Solution Approach 2:
The patent extracts only the essential immunogenic components from the PCV2b ORF2 protein that are sufficient for cross-protection, eliminating excess antigen material that would cause interference, thus achieving protection with minimal effective dose
3Reliability
If traditional vaccine doses are used, then immunity is established, but multiple administrations are required, especially in young pigs with maternal antibodies
Solution Approach 1:
The genotype change to PCV2b combined with optimized dosing parameters enables the vaccine to overcome maternal antibody interference more effectively, allowing single-dose immunization to establish protective immunity where traditional vaccines required multiple administrations
Solution Approach 2:
The vaccine is designed with enhanced immunogenicity characteristics that prepare the immune system in advance, creating protective immunity in a single administration before maternal antibodies can interfere with subsequent vaccinations, thus eliminating the need for multiple doses
Data Source
Figure 1
Figure 2
AI summary
The present invention pertains to a vaccine comprising an ORF2 encoded protein of porcine circo virus 2 (PCV2) and a pharmaceutically acceptable carrier, for use in a method to protect a pig against an infection with porcine circo virus type 2 by administering the vaccine to the pig, wherein the vaccine comprises less than 20 µg per dose of the ORF2 encoded protein, the protein being of a porcine circo virus of genotype 2b.